Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Heat-labile enterotoxin (LT) is a major virulence factor produced by enterotoxigenic Escherichia coli (ETEC), which is a primary cause of diarrhea in travelers and children in low-income countries (UniProt P06717). The toxin is an AB5-type protein consisting of a catalytic A subunit and a pentameric B subunit that binds to GM1 ganglioside receptors on host cell surfaces (PubMed: 15175434). Detoxified LTh refers to human-derived LT variants, such as LT(R192G) or dLT, which have been genetically engineered to eliminate the ADP-ribosyltransferase activity responsible for toxicity while maintaining potent immunogenic properties (PubMed: 22431647). These detoxified forms are primarily utilized as mucosal adjuvants in vaccine development to stimulate robust secretory IgA and systemic IgG responses against ETEC (PubMed: 28919436). By enhancing the immune system's recognition of co-administered antigens, detoxified LTh plays a critical role in the design of oral vaccines like ETVAX, which aim to provide broad protection against ETEC-mediated disease (ClinicalTrials.gov: NCT02531802).
The detoxified heat-labile enterotoxin (LTh) acts as a mucosal adjuvant by binding to GM1 ganglioside receptors on intestinal epithelial and immune cells via its B-subunit pentamer (PubMed: 15175434). In its detoxified form, such as the R192G mutant, the A-subunit's ability to ADP-ribosylate the Gs alpha protein is abolished, preventing the elevation of intracellular cAMP and the subsequent diarrheal response (PubMed: 22431647). However, the molecule remains highly immunogenic and facilitates the recruitment and activation of antigen-presenting cells, such as dendritic cells, thereby promoting the induction of both mucosal (IgA) and systemic (IgG) immune responses against co-administered or intrinsic antigens (PubMed: 28919436).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heat-labile enterotoxin of human enterotoxigenic Escherichia coli (LTh).